CMAC National Facility - Drug Product and Secondary Manufacturing
Faster, evidence-based decisions from raw material to finished form
Formulation and process decisions made late or on limited data put development at risk. Scale-up failures, poor solubility and difficult powders delay timelines and consume scarce API. Understanding material properties early provides evidence to make confident manufacturing decisions, and drug product characterisation to inform regulatory submissions.
WHAT SETS US APART
Tablet development, from first milligram to pilot scale
Our integrated facility supports tablet development across a range of processing routes, from raw material characterisation through granulation, tableting, hot melt extrusion and 3D printing. We bring the equipment, expertise and research depth to help you select and develop the right route for your product.
Scientists who work on your problem, not just your samples
Our teams design studies around your specific formulation and manufacturing challenges, interpreting data, connecting results to your decisions and drawing on the full breadth of CMAC's multidisciplinary expertise.
PROCESSING AND ANALYTICAL PLATFORMS
Seven capabilities. One integrated facility.
-
Powder flow, particle size, density, surface, moisture, thermal and rheological analysis, with in-line PAT.
-
Pilot-to-industrial systems, plus the CMAC MicroFeeder for cohesive powders below 10 g/h.
-
Batch and continuous routes with integrated milling, from lab to industrial scale.
-
Feed frame simulation from under 500g of formulation, and the self-driving Tableting CMC DataFactory®.
-
Predictive ASD screening from under 100 mg of API, through to pilot-scale continuous HME.
-
Filament-free printing for simple binary formulations previously considered non-printable.
-
Multi-modal dissolution with real-time imaging that shows how a drug releases, not just when.
Not sure which platform you need?
Our experts will advise on the best approach for your formulation and process.
APPLICATIONS AND IMPACT
We work across the full spectrum of drug product challenges:
Bioavailability enhancement for poorly soluble drugs via amorphous solid dispersions
Continuous manufacturing process development and batch-to-continuous transfer
Drug product characterisation
Lubrication, feedframe and compaction sensitivity studies at minimal material
Oral solid dosage form development — tablets, granules, capsules and printed forms
Scale-up risk assessment from lab to pilot scale
Ready to collaborate?
Whether you're exploring new drug products or solving complex process challenges, we are here to help.
CMAC has achieved two Silver and one Bronze level certifications for integrating sustainable practices in its lab operations.